항염증제 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Anti-Inflammatory Drugs Market was valued at USD 132.1 billion in 2025 and is estimated to grow at a CAGR of 8.5% to reach USD 293.4 billion by 2035.

Market growth is supported by continued progress in immunology research and molecular science, which is enabling the development of more precise and effective therapies. Treatment approaches are steadily shifting away from traditional nonsteroidal anti-inflammatory drugs and corticosteroids toward targeted biologics, monoclonal antibodies, and advanced small-molecule inhibitors. These innovations are improving disease control, reducing side effects, and delivering better long-term outcomes for patients. The market addresses a wide spectrum of acute and chronic inflammatory conditions through multiple therapeutic classes designed to manage inflammation, ease symptoms, and slow disease progression. Strong reimbursement structures and sustained investment in immune-focused drug discovery are reinforcing adoption. Emerging oral therapies and advanced delivery platforms, including extended-duration injectables and less frequent dosing biologics, are enhancing patient convenience and adherence. Overall, the market is evolving toward precision-based, patient-focused treatments supported by innovation-friendly regulatory environments and expanding clinical pipelines.

The anti-inflammatory biologics segment accounted for 75.5% share in 2025 and is expected to grow at a CAGR of 8.6% during 2026-2035. Their leadership position is driven by high clinical effectiveness, selective targeting of inflammatory pathways, and their ability to manage moderate to severe disease states. These therapies deliver both symptom relief and long-term disease modification, making them a preferred option in advanced treatment settings.

The prescription segment generated USD 77.2 billion in 2025, maintaining its dominant position. Prescription-based therapies remain essential for long-term management of inflammatory and autoimmune conditions that require physician supervision and specialized treatment protocols. Broad uptake of biologics and targeted oral drugs, combined with strong reimbursement and hospital-centered distribution, continues to support this segment.

North America Anti-inflammatory Drugs Market held a share of 39.1% in 2025, leading global demand. Market strength is supported by high disease prevalence, well-developed healthcare infrastructure, early access to innovative therapies, and favorable reimbursement policies. Ongoing clinical research activity and a strong pharmaceutical presence further reinforce the region's leadership.

Key companies operating in the Global Anti-inflammatory Drugs Market include Pfizer, AbbVie, Johnson & Johnson, Novartis, Sanofi, AstraZeneca, Eli Lilly and Company, Bristol-Myers Squibb, Amgen, Hoffmann-La Roche, Merck & Co., GlaxoSmithKline, UCB, Abbott Laboratories, Teva Pharmaceutical, and Sun Pharmaceutical. Companies in the anti-inflammatory drugs market are strengthening their competitive position through sustained investment in research and development, particularly in targeted therapies and next-generation biologics. Many players are expanding their pipelines through strategic collaborations, licensing agreements, and acquisitions to access novel mechanisms of action. The focus on oral formulations and long-acting delivery systems is improving patient adherence and market reach. Firms are also prioritizing geographic expansion in high-growth regions while securing strong reimbursement positioning in mature markets.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Drug class trends
  • 2.2.3 Treatment trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Type trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic inflammatory and autoimmune diseases
    • 3.2.1.2 Advancements in targeted immunology and biologic drug development
    • 3.2.1.3 Supportive regulatory pathways and accelerated approvals
    • 3.2.1.4 Rising awareness, diagnosis rates, and access to specialty care
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs and long-term affordability concerns
    • 3.2.2.2 Safety concerns and long-term tolerability risks
  • 3.2.3 Market opportunities
    • 3.2.3.1 Next-generation oral therapies and improved patient convenience
    • 3.2.3.2 Lifecycle management through biosimilars and combination therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Future market trends
• 3.6 Pricing analysis
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Anti-inflammatory biologics
• 5.3 Nonsteroidal anti inflammatory drugs (NSAIDS)
• 5.4 Corticosteroids
• 5.5 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Rheumatologic diseases
  • 6.2.1 Rheumatoid arthritis
  • 6.2.2 Osteoarthritis
  • 6.2.3 Psoriatic arthritis
  • 6.2.4 Ankylosing spondylitis
  • 6.2.5 Other inflammatory arthritis
• 6.3 Dermatological diseases
  • 6.3.1 Psoriasis
  • 6.3.2 Atopic dermatitis
  • 6.3.3 Hidradenitis suppurativa
  • 6.3.4 Other inflammatory skin diseases
• 6.4 Gastrointestinal diseases
  • 6.4.1 Inflammatory bowel disease (IBD)
  • 6.4.2 Eosinophilic esophagitis
  • 6.4.3 Other inflammatory GI disorders
• 6.5 Respiratory diseases
  • 6.5.1 Asthma
  • 6.5.2 Chronic obstructive pulmonary disease (COPD)
  • 6.5.3 Allergic rhinitis
  • 6.5.4 Other inflammatory respiratory diseases
• 6.6 Neurological disorders
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Injectable
• 7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Prescription
• 8.3 Over the counter (OTC)

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AbbVie
• 11.2 Abbott Laboratories
• 11.3 AbbVie
• 11.4 Amgen
• 11.5 AstraZeneca
• 11.6 Bristol-Myers Squibb
• 11.7 Eli Lilly and Company
• 11.8 GlaxoSmithKline
• 11.9 Hoffmann-La Roche
• 11.10 Johnson & Johnson
• 11.11 Merck & Co.
• 11.12 Novartis
• 11.13 Pfizer
• 11.14 Sanofi
• 11.15 Sun Pharmaceutical Industries
• 11.16 Teva Pharmaceutical
• 11.17 UCB